Class 4 Medicines Defect Information: Kolanticon Gel 200ml (Intrapharm Laboratories Ltd)

Class 4 Medicines Defect Information: Kolanticon Gel 200ml (Intrapharm Laboratories Ltd)

November 9, 2020

Class 4 Medicines Defect Information: Kolanticon Gel 200ml PL 17509/0084 (Intrapharm Laboratories Ltd)

Drug alert number: EL (20) A/51

Date issued: 9 November 2020

The Medicines and Health products Regulatory Agency (MHRA) has issued a class 4 medicines defect information notice for:

Kolanticon Gel 200ml PL 17509/0084 (Intrapharm Laboratories Ltd)

Intrapharm Laboratories Ltd has informed the MHRA that there is a difference in dosage instructions between the carton and label. The Patient Information Leaflet (PIL) and bottle label contain the correct instructions.

The carton instructions for dosing read as follows:

  • ‘Dosage: For Oral use. Two to four 6ml spoonfuls every four hours as required….’

The correct instructions should be:

  • ‘Dosage: For Oral use. ‘Two to four 5ml spoonfuls every four hours as required….’

It was confirmed that the carton with the incorrect dosage instructions had been used to pack only one batch, AA0620. This batch is not being recalled based on a medical risk assessment and consideration that if the maximum daily dosage is taken then an additional 24ml may get consumed in 24 hours. A further consideration is that the standard dosing measurement for a medicine spoon is 5ml; there is no 6ml medicine spoon available. The assessment concluded low risk to patient safety or overdose as a consequence of this dosage instruction error.

Batch number Expiry date Pack size First distributed
AA0620 31/12/2021 200ml 04 Sep 2020

Advice for healthcare professionals

  • When dispensing or providing this product, please check the Marketing Authorisation Holder and the batch number and ensure that patients are aware of the correct dosing instructions as stated in the PIL and on the bottle label.

In the event that the maximum recommended daily dose is exceeded, the adverse effects expected are likely to be non-serious and may include dry mouth, blurred vision and urinary retention. However, the drug is rapidly cleared by the kidneys and has a half-life of 1.8 hours, so any potential adverse effects are quickly reversed on discontinuation.

View full alert here

Contact details for further information

For more information or medical information queries:

Tel: +44 (0)330 1359 437

Email: medinfo@intrapharmlabs.com

 

 



Posted in: ,


More Latest News >

PNA guidance for LPCs published

PSNC and the Department of Health and Social Care (DHSC) have both published guidance on pharmaceutical needs assessments (PNAs). The...

CEO job opportunity at Kent LPC

Are you an exceptional strategic thinking individual who can provide innovative solutions to support and develop community pharmacy? If so, this...